duvelisib

July 10, 2017July 10, 2017

Potential Oral Therapy for Indolent Non-Hodgkin’s Lymphoma, Duvelisib, Shows Efficacy in Phase 2 Trial

News

An investigative oral therapy, duvelisib, was effective in treating indolent non-Hodgkin’s lymphoma among patients who did not respond to Rituxan (rituximab) and chemotherapy or radioimmunotherapy, according to results from a Phase ... Read more

June 20, 2017June 20, 2017

Duvelisib Safe, Effective in Refractory Non-Hodgkin’s Lymphoma Patients, DYNAMO Study Shows

News

Treatment with Verastem’s duvelisib has shown sustained efficacy and safety in a trial with indolent non-Hodgkin’s lymphoma (iNHL) patients who had not responded well to Rituxan (rituximab) and chemotherapy or ... Read more

May 9, 2017

Verastem to Present Long-term Findings on Duvelisib’s Ability to Counter Non-Hodgkin’s Lymphoma

News

Verastem will present long-term findings on duvelisib’s ability to combat non-Hodgkin’s lymphoma at the 14th International Conference on Malignant Lymphoma in Lugano, Switzerland, June 14-17. Forty-six of 129 lymphoma patients in the DYNAMO Phase 2 clinical ... Read more

June 20, 2016June 20, 2016

Phase 2 Study of Candidate for Refractory Indolent Non-Hodgkin Lymphoma Patients So-So

News

Infinity Pharmaceuticals recently announced that its Phase 2 clinical trial Dynamo evaluating the efficacy and safety of duvelisib in patients with refractory indolent non-Hodgkin lymphoma (iNHL) met its primary endpoint but ... Read more

October 21, 2015October 21, 2015

Infinity Pharmaceuticals Presents Product Updates and Announces 120th Patient Enrolled in DYNAMO Study on Indolent Non-Hodgkin Lymphoma

News

Earlier this month Infinity Pharmaceuticals presented updates on the clinical development and commercial strategy for duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, during its Research and Development (R&D) Day. The ... Read more